Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Berotralstat→

Berotralstat Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1809010-50-1
Molecular formula
C30H26F4N6O
Molecular weight
562.6 g/mol
Drug class
Oral plasma kallikrein inhibitorhereditary angioedema prophylactic agent
Mechanism of action
Selectively inhibits plasma kallikrein, reducing cleavage of high-molecular-weight kininogen and formation of bradykinin, a mediator of hereditary angioedema attacks. The previous CYP2D6 mechanism assignment was incorrect; CYP2D6 is relevant to drug-interaction considerations, not its primary pharmacological mechanism.
Indications / reported uses
  • Routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and paediatric patients aged 12 years and older; not indicated for treatment of an acute HAE attack

Sources: US DailyMed — ORLADEYO (berotralstat) prescribing information · FDA — ORLADEYO approval information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Berotralstat Environmental Risk Assessment (ERA) (the Berotralstat ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.